Actively Recruiting
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Led by Vall d'Hebron Institute of Oncology · Updated on 2023-06-23
100
Participants Needed
1
Research Sites
359 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.
CONDITIONS
Official Title
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed Triple Negative Breast Cancer (negative for HER2, ER, and PgR)
- Stage II or III breast cancer based on AJCC 8th edition criteria
- Candidate for neoadjuvant chemotherapy with or without immune checkpoint inhibitor
- At least 18 years old at time of consent
You will not qualify if you...
- Presence of metastatic (stage IV) disease on imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vall d'Hebron Institute of Oncology
Barcelona, Spain, 08035
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here